ACOG: Best evidence for rx of nausea, vomiting in pregnancy

ACOG: best evidence for rx of nausea, vomiting in pregnancy

(HealthDay)—In a practice bulletin published in the September issue of Obstetrics & Gynecology, recommendations are presented for the management of nausea and vomiting of pregnancy.

Noting that nausea and of is a common condition that affects the health of pregnant women and their fetus, and that nausea and vomiting of pregnancy may be minimized by obstetric providers and pregnant women, the Committee on Practice Bulletins reviewed data relating to the diagnosis and management of nausea and vomiting of pregnancy.

The authors note that it can become difficult to control symptoms once nausea and vomiting of pregnancy progresses; early treatment can prevent more serious complications, including hospitalization. Based on good and consistent evidence, the authors recommend three months of prenatal vitamins before conception to reduce the incidence and severity of nausea and vomiting. Vitamin B6 or vitamin B6 plus doxylamine is safe and effective for treatment and should be considered first-line pharmacotherapy. For patients with hyperemesis gravidarum, treatment of hyperthyroidism should not be undertaken without evidence of intrinsic thyroid disease. Limited or inconsistent scientific evidence supports treatment with ginger for reducing symptoms. Methylprednisolone may be efficacious in refractory cases, but it should be a last-resort treatment due to the risk profile.

"The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat of pregnancy" the authors write.

More information: Full Text (subscription or payment may be required)

Journal information: Obstetrics & Gynecology

Copyright © 2015 HealthDay. All rights reserved.

Citation: ACOG: Best evidence for rx of nausea, vomiting in pregnancy (2015, August 20) retrieved 19 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Case report: cannabinoid hyperemesis syndrome


Feedback to editors